Ardelyx Inc  

(Public, NASDAQ:ARDX)   Watch this stock  
Find more results for ARDX
+0.15 (2.83%)
Mar 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.25 - 5.55
52 week 4.05 - 15.40
Open 5.35
Vol / Avg. 562,836.00/310,670.00
Mkt cap 266.40M
P/E     -
Div/yield     -
EPS -2.11
Shares 47.60M
Beta 0.76
Inst. own 86%
Feb 15, 2018
Ardelyx Inc at Leerink Partners Global Healthcare Conference
Jan 10, 2018
Ardelyx Inc at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin -60.68% -237.95%
Operating margin 26.10% -155.04%
EBITD margin - -148.75%
Return on average assets -67.92% -53.87%
Return on average equity -76.87% -60.12%
Employees 75 -
CDP Score - -


34175 Ardenwood Blvd
FREMONT, CA 94555-3653
United States - Map
+1-510-7457047 (Phone)
+1-510-7450493 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.

Officers and directors

David M. Mott Independent Chairman of the Board
Age: 51
Bio & Compensation  - Reuters
Michael G. Raab President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Mark E. Kaufmann Chief Financial Officer, Principal Accounting Officer
Age: 49
Bio & Compensation  - Reuters
Reginal Seeto Chief Operating Officer, Executive Vice President
Age: 45
Bio & Compensation  - Reuters
Jeremy S. Caldwell Ph.D. Executive Vice President, Chief Scientific Officer
Age: 48
Bio & Compensation  - Reuters
Elizabeth Grammer Esq. Senior Vice President, General Counsel
Age: 53
Bio & Compensation  - Reuters
David P. Rosenbaum Ph.D. Chief Development Officer
Age: 56
Bio & Compensation  - Reuters
Robert B. Bazemore Jr. Independent Director
Age: 49
Bio & Compensation  - Reuters
William C. Bertrand Jr. Esq. Independent Director
Age: 52
Bio & Compensation  - Reuters
Annalisa M. Jenkins Independent Director
Age: 52
Bio & Compensation  - Reuters